Gossamer Bio (GOSS) News
NASDAQ: GOSSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.72-0.51 (-4.54%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GOSS news summary
We found 3 recent headlines mentioning Gossamer Bio (GOSS): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Business Wire. For price context, GOSS is down 4.54% at $10.72. The most recent story, "Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update", was published by Business Wire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Gossamer Bio headlines
- Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business UpdateSAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…Business Wire
- TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesTG Therapeutics (TGTX) delivered earnings and revenue surprises of +25.00% and +5.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqTGTX, GOSS
- Gossamer Bio Stockholders Approve Share Issuance Proposal Under Securities Purchase Agreement Dated August 20, 2026Gossamer Bio, Inc. held a special meeting of stockholders on October 27, 2026. Stockholders approved, in accordance with Nasdaq Listing Rules 5635(c) and 5635(d), the potential issuance of shares of…NasdaqGOSS, HEI.A